Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | OPRM1 | P35372 | 6/20 | 0.39 |
| ▸ | OPRK1 | P41145 | 6/20 | 0.39 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.37 |
| ▸ | F10 | P00742 | 5/20 | 0.36 |
| ▸ | ALOX5AP | P20292 | 2/20 | 0.36 |
| ▸ | FEN1 | P39748 | 2/20 | 0.36 |
| ▸ | PRSS1 | P07477 | 3/20 | 0.34 |
| ▸ | F2 | P00734 | 2/20 | 0.34 |
| ▸ | PRSS2 | P07478 | 2/20 | 0.34 |
| ▸ | PRSS3 | P35030 | 2/20 | 0.34 |
| ▸ | PSIP1 | O75475 | 1/20 | 0.33 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6066478 | 1.00 | LMNA (0.39) | LMNAGAAOPRM1OPRK1TAAR1 | |
| SCHEMBL654704 | 0.87 | LMNA (0.39) | LMNAGAAOPRM1OPRK1ALOX5AP | |
| SCHEMBL7567012 | 0.87 | LMNA (0.39) | LMNAGAAOPRM1OPRK1ALOX5AP | |
| SCHEMBL7567015 | 0.87 | LMNA (0.39) | LMNAGAAOPRM1OPRK1ALOX5AP | |
| SCHEMBL489379 | 0.83 | LMNA (0.58) | LMNAGAAOPRM1OPRK1ALOX5AP | |
| SCHEMBL6066480 | 0.81 | LMNA (0.41) | LMNAGAAOPRM1OPRK1ALOX5AP | |
| SCHEMBL6066470 | 0.81 | LMNA (0.41) | LMNAGAAOPRM1OPRK1ALOX5AP | |
| SCHEMBL8511462 | 0.81 | LMNA (0.41) | LMNAGAAOPRM1OPRK1ALOX5AP | |
| SCHEMBL22588383 | 0.76 | CHRM1 (0.42) | LMNAGAATAAR1 | |
| SCHEMBL22588384 | 0.76 | CHRM1 (0.42) | LMNAGAATAAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7067665-B2 | Oxybenzamide derivatives useful for inhibiting factor Xa or Vlla | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2006-06-27 | — | — | US | disclosed |
| US-6953857-B2 | Oxybenzamide derivatives useful for inhibiting factor Xa or viia | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2005-10-11 | — | — | US | disclosed |
| US-20050165058-A1 | Oxybenzamide derivatives useful for inhibiting factor Xa or Vlla | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2005-07-28 | — | — | US | disclosed |
| EP-1349847-B1 | OXYBENZAMIDES DERIVATIVES AS FACTOR XA INHIBITORS | AVENTIS PHARMA GMBH (DE) | 2005-04-20 | — | — | EP | disclosed |
| CN-1481376-A | HYDROXYBENZAMIDE DERIVATIVES AS FACTOR XA INHIBITORS | ���ĵ�˹ҩ��¹�����˾ | 2004-03-10 | — | — | CN | disclosed |
| EP-1349847-A1 | OXYBENZAMIDES DERIVATIVES AS FACTOR XA INHIBITORS | Aventis Pharma Deutschland GmbH (DE) | 2003-10-08 | — | — | EP | disclosed |
| US-20020198195-A1 | New oxybenzamide derivatives useful for inhibiting factor Xa or VIIa | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2002-12-26 | — | — | US | disclosed |
| WO-2002051831-A1 | OXYBENZAMIDES DERIVATIVES AS FACTOR XA INHIBITORS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2002-07-04 | — | — | WO | disclosed |
| EP-1217000-A1 | Inhibitors of factor Xa and factor VIIa | Aventis Pharma Deutschland GmbH (DE) | 2002-06-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050165058-A1 | Oxybenzamide derivatives useful for inhibiting factor Xa or Vlla | F12, F11, F5 | LMNA 59/4885GAA 40/4885OPRM1 189/4885 |
| US-20020198195-A1 | New oxybenzamide derivatives useful for inhibiting factor Xa or VIIa | F9, F11, F5 | LMNA 324/4885GAA 61/4885OPRM1 302/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.